Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) published a new CEO Corner segment on Nov 26, 2025.

In the segment, President and CEO Brad Hauser discussed two priorities: protecting the company’s platform via intellectual property, and exploring expansion beyond its initial pancreatic cancer focus into potential cardiovascular, pulmonary, and chronic pain targets.

The segment is available on the company website for investors and stakeholders seeking management commentary on strategy and pipeline direction.

News Market Reaction – AMIX

+10.19%

13 alerts

+10.19% News Effect

+7.4% Peak in 7 hr 48 min

+$691K Valuation Impact

$7M Market Cap

0.0x Rel. Volume

On the day this news was published, AMIX gained 10.19%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.4% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $691K to the company's valuation, bringing the market cap to $7M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.4099 Vol: Volume 127,473 is far bel...

low vol

$0.4099 Last Close

Volume Volume 127,473 is far below the 20-day average of 16,097,537, suggesting limited trading interest ahead of this update. low

Technical Shares trade below the 200-day moving average at 1.43, reflecting a weak longer-term trend.

Peers on Argus

Peer moves are mixed: MOVE down 5.46%, HSDT down 4.03%, HSCS up 0.77%, with othe...

1 Up 1 Down

Peer moves are mixed: MOVE down 5.46%, HSDT down 4.03%, HSCS up 0.77%, with others flat. AMIX up 1.78% appears more company-specific than sector-driven.

Historical Context

5 past events · Latest: Nov 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 26	Strategy update	Positive	+10.2%	CEO commentary on IP strategy and expansion beyond pancreatic cancer.
Nov 18	Private placement	Negative	-17.4%	Dilutive $5.0M private placement with Series C warrants and pre-funded warrants.
Nov 17	Clinical data update	Positive	+58.2%	Post-hoc PoC 1 subgroup results showing sustained QOL improvements in pancreatic cancer.
Oct 24	Conference presentation	Positive	+0.0%	TCT conference podium talks on first-in-human transvascular nerve ablation study.
Oct 16	Investor conference	Positive	-1.8%	Maxim Growth Summit presentation highlighting nerve-sensing and ablation platform.

Pattern Detected

Positive clinical and strategic communications have coincided with sharp gains, while financing-related actions have aligned with selling pressure.

Recent Company History

Over the past months, Autonomix has combined clinical progress, investor outreach, and financing activity. A post-hoc analysis of its PoC 1 study in pancreatic cancer on Nov 17, 2025 coincided with a 58.18% move, while the Maxim Growth Summit and TCT conference appearances saw minimal impact. The $5.0 million private placement on Nov 18, 2025 aligned with a -17.38% reaction. On Nov 26, 2025, the CEO Corner segment focused on IP protection and expansion beyond pancreatic cancer, tying management commentary to this evolving strategy.

Regulatory & Risk Context

Active S-3 Shelf · $7.7 million

Shelf Active

Active S-3 Shelf Registration 2025-11-26

$7.7 million registered capacity

An effective S-3 shelf filed on Nov 26, 2025 registers 13,504,998 warrant-related shares for resale. While Autonomix would not receive proceeds from resales, full cash exercise of the common warrants could bring in up to $7.7 million and significantly increase the share count, reinforcing existing dilution and capital-raising themes highlighted across recent SEC filings.

Market Pulse Summary

The stock surged +10.2% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +10.2% in the session following this news. A strong positive reaction aligns with past patterns where strategic and clinical updates coincided with sharp gains, such as the 58.18% move after the PoC 1 analysis. However, investors also faced notable dilution from the recent $5.0 million private placement and warrant-linked S-3 registering 13,504,998 shares, which expanded potential supply. Sustainability of any large move has historically depended on how quickly subsequent capital-raising or dilution events followed upbeat announcements.

Key Terms

pancreatic cancer, cardiovascular, pulmonary

3 terms

pancreatic cancer medical

"beyond its initial target, pancreatic cancer, into potential future targets"

Pancreatic cancer is a disease in which cells in the pancreas grow out of control, forming a tumor that disrupts the organ’s role in digestion and blood-sugar regulation; because it often spreads early and is hard to detect, outcomes tend to be poor. For investors, it matters because diagnosis rates, treatment advances, drug approvals, and clinical trial results can strongly affect the value of biotech and healthcare companies—think of a breakthrough therapy as a new part that could fix a failing engine and reshape market expectations.

cardiovascular medical

"into potential future targets in the cardiovascular space, pulmonary space"

Relating to the heart and the network of blood vessels that pump and carry blood through the body — like the body’s engine and plumbing working together. Investors pay attention because conditions, treatments, devices, and drugs tied to this system drive large health care spending, regulatory reviews, and market demand; breakthroughs, safety issues, or trial results can quickly change a company’s revenue prospects and stock value.

pulmonary medical

"cardiovascular space, pulmonary space as well as chronic pain"

Relating to the lungs and the system that moves air in and out of the body; pulmonary describes anything involving breathing, oxygen exchange, or lung tissue. Investors care because pulmonary problems and treatments affect demand for medical services, drug development, equipment, and worker productivity—similar to how a clogged air filter reduces engine performance, impaired lungs can slow economic activity for healthcare providers, insurers, and companies developing therapies or devices.

AI-generated analysis. Not financial advice.

THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Brad Hauser, President and CEO of Autonomix, discussed two key areas that are shaping the Company’s path forward: protecting the strength of its platform through intellectual property, and exploring new opportunities beyond its initial target, pancreatic cancer, into potential future targets in the cardiovascular space, pulmonary space as well as chronic pain.

The CEO Corner segment is now available here.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

FAQ

What did Autonomix (AMIX) announce in the CEO Corner on Nov 26, 2025?

Autonomix published a CEO Corner where CEO Brad Hauser discussed strengthening intellectual property and exploring new targets beyond pancreatic cancer.

Where can investors watch the Autonomix (AMIX) CEO Corner segment published Nov 26, 2025?

The CEO Corner segment is available on Autonomix’s corporate website via the investor or news section.

Which new therapeutic areas did Autonomix (AMIX) mention exploring in the Nov 26, 2025 CEO Corner?

The company said it is exploring potential targets in the cardiovascular, pulmonary, and chronic pain areas.

Did Autonomix (AMIX) provide financial guidance or clinical data in the Nov 26, 2025 CEO Corner?

No; the CEO Corner focused on strategy and intellectual property protections and did not include financial guidance or clinical data.

Who spoke in the Autonomix (AMIX) CEO Corner released Nov 26, 2025?

The segment features comments from Brad Hauser, President and CEO of Autonomix.

What is the strategic purpose of the CEO Corner for Autonomix (AMIX) investors?

The CEO Corner provides management commentary on strategy, IP protection plans, and potential expansion into new therapeutic areas to inform investors.